Partner With Us NRI

Indoco Remedies Ltd share Price

Company details

6M Return -11.44%
1Y Return 0.13%
Mkt Cap.(Cr) 3,245.06
Volume 118,770
Div Yield 0.64%
OI Chg %
Volume 118,770

Open Free Trading Account Online with ICICIDIRECT

About The Stock

    Indoco manufactures and markets branded formulations and APIs for the domestic and export markets. In domestic formulations, through its nine marketing divisions, the company serves a range of specialties.

    • Domestic formulations accounted for 54% of revenues. Major therapies are: respiratory, anti-infectives, stomatologicals, gastrointestinals and vitamins
    • Formulation exports accounted for 41% (regulated markets:81%) of revenues while APIs contributed 4% with remaining coming from CRAMS


    Indoco reported robust revenue growth in both domestic (up 39% YoY to ₹ 193 crore) and export formulations (up 44% YoY to ₹ 190 crore)

    • Sales were up 34% YoY to ₹ 409 crore
    • EBITDA was at ₹ 81 crore, up 47% YoY with margins at 19.7%
    • PAT for Q4 was at ₹ 40 crore (up 62% YoY)

Click here for full recommendation

Research view on more stocks

Indoco Remedies Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Indoco Remedies Ltd.

Pharmaceuticals company Indoco Remedies announced Q4FY23 & FY23 results:

  • Q4FY23:
    • During Q4FY23, revenues grew by 6.9% at Rs 428.0 crore, as against Rs 400.3 crore in Q4FY22
    • EBIDTA to net sales for Q4FY23 is 15.0% at Rs 64.2 crore, compared to 20.1% at Rs 80.5 crore in Q4FY22
    • For Q4FY23, the Profit After Tax is at Rs 25.4 crore, compared to Rs 40.4 crore in Q4FY22
    • Profit After Tax with other comprehensive income is at Rs 29.7 crore, compared to Rs 35.6 crore in Q4FY22
  • FY23:
    • For FY23, the revenues grew by 9.0% at Rs 1,638.1 crore, as against Rs 1,502.7 crore in FY22
    • EBIDTA to net sales for FY23 is 17.4% at Rs 284.9 crore, compared to 21.8% at Rs 327.0 crore in FY22
    • For FY23, the Profit After Tax is at Rs 141.4 crore, compared to Rs 154.5 crore in FY22
    • Profit After Tax with other comprehensive income is at Rs 142.8 crore, compared to Rs 149.2 crore in FY22

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our performance this year is a function of a predictable performance of India business, free of COVID impact, accompanied by a good performance of Export business”.


Result PDF

View Other Company Results


Investment recommendation

Call Date
25 Jan 2023
Entry Price 348.00
Target Price 440.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Indoco Remedies Ltd Stocks COMPARISION


Equity Capital: 904.64 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 2,333.12 37,369.27
LAST 3M 16,668.82 53,102.69
LAST 6M 64,410.78 32,565.35
LAST 12M 119,684.93 75,969.00
Indoco Remedies Limited - Notice of Meeting

May 29, 2023 l NSE Announcement

Indoco Remedies Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 26, 2023 l NSE Announcement

Date Action Type Ratio
Sep 14, 2022 Dividend 75
Sep 14, 2022 Dividend 37.5
Sep 17, 2021 Dividend 75

Indoco Remedies Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Indoco Remedies Ltd. is a fully integrated, research-oriented pharma company. It manufactures and markets Active Pharmaceutical Ingredients (APIs) and Formulations (Finished Dosage Forms). It was incorporated in 1947, with its headquarters in Mumbai. During FY 2021-2022, the company generated a total revenue of Rs 1,543.08 crore, up 23.98% from the previous financial year, 2020-2021. On 31 October 2022, Indoco Remedies Ltd.’s market capitalisation was Rs 3,262 crore.

    The company is listed on the Bombay Stock Exchange with the code 532612, and on the National Stock Exchange with the code INDOCO. It is also listed on the MCX Stock Exchange.

    Indoco Remedies Ltd. has a well-built brand portfolio with a number of products in various therapeutic segments. It includes high-growth lifestyle segments like cardiovascular, musculoskeletal, anti-diabetics, central nervous system, dental care, and nutrition. The company has a strong presence in the international market across 55 countries and employs close to 6000 personnel with more than 300 skilled scientists. It has nine manufacturing facilities, of which three are for APIs and six for finished dosages.

    On 30 June 2022, the company’s shareholding pattern showed a promoter holding of 58.69%, an FII holding of 1.17%, a DII holding of 18.08%, and a public holding of 22.06%. The leading promoter is Spa Holdings Pvt Ltd., with a 19.9% share. In the June 2022 quarter, mutual fund holdings decreased from 17.52% to 17.39%, while FPI holdings increased from 1.15% to 1.17%.

    The company’s board of directors comprises Mr Suresh G Kare, Mr Sundeep V Bambolkar, Mr Rajiv P Kakodkar, Dr Anand Nadkarni, Mr D M Gavaskar, Mr Abhijit Yashwant Gore, Dr (Ms) Vasudha V Kamat, and Ms Aditi Kare Panandikar. The auditors are Gokhale & Sathe. As of 30 June 2022, the company’s total outstanding shares were 9.22 crores.

    On 31 October 2022, the company’s share’s closing price was Rs 353.60 on BSE. On NSE, its closing price was Rs 354. The share touched a 52-week high of Rs 498 and a 52-week low of Rs 307.65. Investors earned a six-month return of -8.63% and a one-year return of -21.40%.

    The company’s peers include Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Divis Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Indoco House 166 C S T Road, Santacruz (East) Kalina, Mumbai, Maharashtra, 400098

Tel : 91-022-26541851-55
Email : jagdishs:indoco.com
Website : http://www.indoco.com

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532612
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE873D01024

FAQ’s on Indoco Remedies Ltd Shares

You can buy Indoco Remedies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Indoco Remedies Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 31, 2023 03:57 PM the closing price of Indoco Remedies Ltd was ₹ 352.15.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 31, 2023 03:57 PM, the market cap of Indoco Remedies Ltd stood at ₹ 3,245.06.

The latest PE ratio of Indoco Remedies Ltd as of May 31, 2023 03:57 PM is 22.69

The latest PB ratio of Indoco Remedies Ltd as of May 31, 2023 03:57 PM is 0.32

The 52-week high of Indoco Remedies Ltd is ₹ 423.90 while the 52-week low is ₹ 306.40

According to analyst recommendations, Indoco Remedies Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app